US Pharma MarketingFDA says initial rejections of new drugs have declined
An FDA report pushes back on claims it Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power…
The FDA is looking to dispel what it says are inaccurate claims that it's increasingly rejecting new drugs after an initial review.
The claims stem from a 2027 budget-related report from ...
Source: Endpoints News